Henry Ford Health

Henry Ford Health Scholarly Commons
Surgery Articles

Surgery

11-12-2020

A Randomized Trial Comparing Antibiotics with Appendectomy
for Appendicitis
David R. Flum
Giana H. Davidson
Sarah E. Monsell
Nathan I. Shapiro
Stephen R. Odom

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/surgery_articles

Recommended Citation
Flum DR, Davidson GH, Monsell SE, Shapiro NI, Odom SR, Sanchez SE, Drake FT, Fischkoff K, Johnson J,
Patton JH, Evans H, Cuschieri J, Sabbatini AK, Faine BA, Skeete DA, Liang MK, Sohn V, McGrane K, Kutcher
ME, Chung B, Carter DW, Ayoung-Chee P, Chiang W, Rushing A, Steinberg S, Foster CS, Schaetzel SM, Price
TP, Mandell KA, Ferrigno L, Salzberg M, DeUgarte DA, Kaji AH, Moran GJ, Saltzman D, Alam HB, Park PK,
Kao LS, Thompson CM, Self WH, Yu JT, Wiebusch A, Winchell RJ, Clark S, Krishnadasan A, Fannon E,
Lavallee DC, Comstock BA, Bizzell B, Heagerty PJ, Kessler LG, and Talan DA. A Randomized Trial
Comparing Antibiotics with Appendectomy for Appendicitis. N Engl J Med 2020.

This Article is brought to you for free and open access by the Surgery at Henry Ford Health Scholarly Commons. It
has been accepted for inclusion in Surgery Articles by an authorized administrator of Henry Ford Health Scholarly
Commons.

Authors
David R. Flum, Giana H. Davidson, Sarah E. Monsell, Nathan I. Shapiro, Stephen R. Odom, Sabrina E.
Sanchez, F. Thurston Drake, Katherine Fischkoff, Jeffrey Johnson, Joe H. Patton, Heather Evans, Joseph
Cuschieri, Amber K. Sabbatini, Brett A. Faine, Dionne A. Skeete, Mike K. Liang, Vance Sohn, Karen
McGrane, Matthew E. Kutcher, Bruce Chung, Damien W. Carter, Patricia Ayoung-Chee, William Chiang, Amy
Rushing, Steven Steinberg, Careen S. Foster, Shaina M. Schaetzel, Thea P. Price, Katherine A. Mandell, Lisa
Ferrigno, Matthew Salzberg, Daniel A. DeUgarte, Amy H. Kaji, Gregory J. Moran, Darin Saltzman, Hasan B.
Alam, Pauline K. Park, Lillian S. Kao, Callie M. Thompson, Wesley H. Self, Julianna T. Yu, Abigail Wiebusch,
Robert J. Winchell, Sunday Clark, Anusha Krishnadasan, Erin Fannon, Danielle C Lavallee, Bryan A.
Comstock, Bonnie Bizzell, Patrick J. Heagerty, Larry G. Kessler, and David A. Talan

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
surgery_articles/452

new england
journal of medicine
The

established in 1812

November 12, 2020

vol. 383

no. 20

A Randomized Trial Comparing Antibiotics
with Appendectomy for Appendicitis
The CODA Collaborative*

a bs t r ac t
BACKGROUND

Antibiotic therapy has been proposed as an alternative to surgery for the treatment
of appendicitis.
METHODS

We conducted a pragmatic, nonblinded, noninferiority, randomized trial comparing antibiotic therapy (10-day course) with appendectomy in patients with appendicitis at 25 U.S. centers. The primary outcome was 30-day health status, as assessed
with the European Quality of Life–5 Dimensions (EQ-5D) questionnaire (scores
range from 0 to 1, with higher scores indicating better health status; noninferiority margin, 0.05 points). Secondary outcomes included appendectomy in the antibiotics group and complications through 90 days; analyses were prespecified in
subgroups defined according to the presence or absence of an appendicolith.
RESULTS

In total, 1552 adults (414 with an appendicolith) underwent randomization; 776
were assigned to receive antibiotics (47% of whom were not hospitalized for the
index treatment) and 776 to undergo appendectomy (96% of whom underwent a
laparoscopic procedure). Antibiotics were noninferior to appendectomy on the
basis of 30-day EQ-5D scores (mean difference, 0.01 points; 95% confidence interval [CI], −0.001 to 0.03). In the antibiotics group, 29% had undergone appendectomy by 90 days, including 41% of those with an appendicolith and 25% of those
without an appendicolith. Complications were more common in the antibiotics
group than in the appendectomy group (8.1 vs. 3.5 per 100 participants; rate ratio,
2.28; 95% CI, 1.30 to 3.98); the higher rate in the antibiotics group could be attributed to those with an appendicolith (20.2 vs. 3.6 per 100 participants; rate ratio,
5.69; 95% CI, 2.11 to 15.38) and not to those without an appendicolith (3.7 vs. 3.5
per 100 participants; rate ratio, 1.05; 95% CI, 0.45 to 2.43). The rate of serious
adverse events was 4.0 per 100 participants in the antibiotics group and 3.0 per
100 participants in the appendectomy group (rate ratio, 1.29; 95% CI, 0.67 to 2.50).
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CONCLUSIONS

For the treatment of appendicitis, antibiotics were noninferior to appendectomy on
the basis of results of a standard health-status measure. In the antibiotics group,
nearly 3 in 10 participants had undergone appendectomy by 90 days. Participants
with an appendicolith were at a higher risk for appendectomy and for complications than those without an appendicolith. (Funded by the Patient-Centered Outcomes Research Institute; CODA ClinicalTrials.gov number, NCT02800785.)
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ppendectomy has long been the
standard treatment for appendicitis, even
though successful use of antibiotic therapy as an alternative was reported more than 60
years ago.1 Although there have been several
randomized trials of antibiotics for appendicitis
in adults,2-7 exclusion of important subgroups (in
particular, patients with an appendicolith, who
may be at an increased risk for complications),
small sample sizes, and questions about applicability to the general population have limited the
use of this treatment.8 As recently as 2014, more
than 95% of U.S. patients with appendicitis underwent appendectomy.9 However, with the pandemic of coronavirus disease 2019 (Covid-19),
health systems and professional societies such
as the American College of Surgeons10 have suggested reconsideration of many aspects of care
delivery, including the role of antibiotics in the
treatment of appendicitis.
We conducted the Comparison of Outcomes
of Antibiotic Drugs and Appendectomy (CODA)
trial to compare antibiotic therapy with appendectomy in adults with appendicitis, including
those with an appendicolith. The trial design
was based on recognition that not all patients
prioritize the multiple outcomes related to appendicitis care in the same way. An overall measure
of health status was used for the primary outcome, and analyses of several secondary clinical
and patient-reported outcomes, complications,
and time spent in health care settings were performed. We had initially planned to report the
results after all the participants had at least 1 year
of follow-up, but given the Covid-19–related interest in the management of appendicitis, we
describe results based on the first 90 days after
randomization.

of

m e dic i n e

cal sites participating in the University of Washington–based Comparative Effectiveness Research
Translation Network15 approved the protocol,
and the participants provided written informed
consent. The authors vouch for the completeness
and accuracy of the data and the fidelity of the
trial to the protocol.
Trial Population

Consecutive English- or Spanish-speaking adults
(≥18 years of age) in emergency departments
who had appendicitis that had been confirmed
on imaging were approached by research coordinators. On the basis of a previous trial6 suggesting that patients with an appendicolith had an
increased risk of complicated appendicitis, patients with evidence of an appendicolith on imaging were included in a prespecified subgroup.
Patients were excluded from the trial if they had
septic shock, diffuse peritonitis, recurrent appendicitis, evidence of severe phlegmon on imaging (if the surgeon determined that a more
extensive operation, such as ileocolectomy, was
likely to be performed), walled-off abscess, free
air or more than minimal free fluid, or evidence
suggestive of neoplasm. Other exclusion criteria
are provided in the Supplementary Appendix, available at NEJM.org. In the absence of these conditions, evidence of perforation on imaging was
not an exclusion criterion. Sites were regularly
audited to confirm that all patients with appendicitis were screened. The consent process included a standardized informational video (or pamphlet) in English (https://youtu.be/EQ8Iyc4_55k)
or Spanish (https://youtu.be/5kTdVoq0GZ4). Consenting participants were randomly assigned to
a treatment group by the data coordinating
center. Randomization was performed with the
use of permuted blocks (random block sizes of
4, 6, and 8) and was stratified according to reMe thods
cruitment site and appendicolith status (present
Trial Design and Oversight
or absent). Those who declined to undergo ranThe CODA trial was funded by the Patient-Cen- domization were invited to participate in an
tered Outcomes Research Institute. The trial observational cohort study.11
design has been described previously,11 and the
protocol, including the statistical analysis plan, Treatments
is available with the full text of this article at Participants who were randomly assigned to the
NEJM.org. The trial was designed with the en- antibiotics group received an intravenous formugagement of patient stakeholders12,13 to identify lation for at least 24 hours, followed by pills, for
outcomes that they considered to be most im- a 10-day total course. Clinical teams selected
portant.14 Institutional review boards at 25 clini- antibiotics from Surgical Infection Society and
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Infectious Diseases Society of America guidelines for intraabdominal infections (Fig. S1 in
the Supplementary Appendix).16,17 Participants
were either hospitalized for the administration
of intravenous antibiotics or were discharged
from the emergency department after they had
received intravenous antibiotics for 24 hours or
with 24 hours of bioavailability. Standard discharge criteria included intake of liquids without
difficulty, adequate pain control, and an improving clinical condition. Appendectomy was recommended if diffuse peritonitis or septic shock
developed at any time or if worsening signs and
symptoms developed after 48 hours of antibiotics; however, these criteria were not required to
be met. In the absence of these conditions, participants were encouraged to continue taking
antibiotics, and the decision to perform appendectomy was ultimately made by the treating
clinician. The protocol did not specify how to
manage recurrent appendicitis or symptoms or
how to address patients’ appendix-related concerns. In participants who were randomly assigned to the appendectomy group, laparoscopic
and conventional (open) surgical approaches were
allowed; the technique was not standardized.
Usual preoperative and postoperative care and
discharge criteria were used.
The amount of analgesic agents or pain-control medications provided was not standardized
or monitored in either treatment group. In both
groups, the protocol allowed for crossover on
the basis of participant and clinician decision
making.
Outcomes and Measures

The primary outcome was 30-day health status,
as assessed with the use of the European Quality of Life–5 Dimensions (EQ-5D) questionnaire18
(scores range from 0 to 1, with higher scores
indicating better health status; minimal clinically important difference, 0.05 points19; https://
euroqol.org). Participants were to be contacted
at 24 hours after discharge and surveyed by telephone, mail, or email at 1, 2, and 4 weeks, quarterly for a year, and then yearly. Secondary outcomes included patient-reported resolution of
symptoms, which was defined as the absence of
pain, tenderness, and fever; serious adverse
events; National Surgical Quality Improvement
Program (NSQIP)–defined complications at the

n engl j med 383;20

time of the index treatment or during followup,20 including site-related infectious complications (defined as incisional infections or organ–
space infections [abscesses]), specifically those
that led to percutaneous drainage procedures;
reactions to antibiotics that led to a health care
encounter; Clostridioides difficile infections; more
extensive procedures (e.g., small-bowel or colon
resection, reoperation, laparotomy, colostomy, or
ileostomy); appendiceal perforation found during an operation or on pathological review; appendiceal neoplasm; and appendectomy in the
antibiotics group (Table S1). Visits to the emergency department or urgent care clinic for related
symptoms, days in the emergency department
or hospital related to appendicitis symptoms or
treatment-related complications, and days of
missed work for the participant and the caregiver were recorded. Serious adverse events were
adjudicated by an independent safety monitor to
confirm severity and relatedness to treatment.
Statistical Analysis

Under the assumption of a mean (±SD) score on
the EQ-5D of 0.90±0.12 after treatment for appendicitis,21 we calculated that a sample of 1552
participants would give the trial sufficient power
(>82%) to rule out a between-group difference in
the EQ-5D score as small as 0.05 points, on the
basis of follow-up data for 90% of the participants at 30 days. Within an intention-to-treat
framework, we assessed 30-day EQ-5D scores
with the use of a linear regression model with
indicators for treatment group, as well as for
recruitment site and appendicolith status (randomization stratification factors). Our primary
analysis included participants who completed all
items on the 30-day EQ-5D survey. The estimated
treatment effect and 97.5% one-sided confidence
interval were analyzed with the use of a prespecified noninferiority margin of −0.05 points.22
There was no adjustment for multiplicity in analyses of secondary outcomes, and these analyses
should be considered exploratory. Details regarding stopping rules are provided in the Supplementary Appendix. An independent data and
safety monitoring board reviewed three formal
interim analyses, which were performed annually over the course of the trial, and did not
recommend stopping the trial. To address potential selection bias, we performed a secondary
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8168 Patients with appendicitis
were assessed for eligibility
3987 Were excluded
267 Did not speak English or Spanish
1589 Were excluded for clinical reasons
853 Had appendix-related conditions
368 Had abscess
251 Had severe phlegmon
107 Had free air
296 Had other reason
90 Had ascites
111 Had evidence suggestive of cancer
95 Had peritonitis
736 Had other conditions
130 Had immunodeficiency
148 Were already receiving antibiotics
122 Had contraindication to surgery
376 Had other reason
45 Had sepsis
57 Had cancer
71 Had concurrent hospitalization
42 Were receiving active treatment
for inflammatory bowel syndrome
26 Were undergoing hemodialysis
2 Had a left ventricular assist device
66 Were pregnant
23 Had recent abdominal or pelvic surgery
2 Had uncompensated liver failure
7 Recently underwent implantation
35 Had contraindication to antibiotics
319 Could not be approached within 7 hr
96 Were deemed ineligible by clinical team
1716 Declined to participate
809 Declined before being approached
75 Were deemed ineligible after being approached
834 Declined after being approached

4181 Were enrolled in any cohort

2629 Did not undergo randomization
518 Were enrolled in observational cohort
2111 Were enrolled in EMR-only cohort

1552 Underwent randomization

1910

776 Were assigned to receive antibiotics
564 Did not have appendicolith
212 Had appendicolith

776 Were assigned to undergo appendectomy
574 Did not have appendicolith
202 Had appendicolith

702 (90%) Completed survey at 30-day
follow-up
683 Completed EQ-5D
4 (1%) Withdrew
70 (9%) Were lost to follow-up
771 (99%) Were included in EMR follow-up

695 (90%) Completed survey at 30-day
follow-up
664 Completed EQ-5D
6 (1%) Withdrew
75 (10%) Were lost to follow-up
769 (99%) Were included in EMR follow-up

676 (87%) Completed survey at 90-day
follow-up
4 (1%) Withdrew
96 (12%) Were lost to follow-up

656 (85%) Completed survey at 90-day
follow-up
6 (1%) Withdrew
114 (15%) Were lost to follow-up
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Figure 1 (facing page). Screening, Enrollment,
Randomization, and Follow-up.
Patients could have more than one exclusion criterion.
The patient surveys and timing of the study were the
same for the observational cohort and the randomized
cohort. The electronic medical record (EMR)–only co‑
hort includes medical record data from the index hospi‑
talization and 4-week and 2-year chart reviews. EQ-5D
denotes European Quality of Life–5 Dimensions.

per-protocol analysis of EQ-5D scores and serious adverse events at 30 days. (Details regarding
the interim and per-protocol analyses are provided in the Supplementary Appendix.) With adjustment for treatment group, recruitment site,
and appendicolith status (if appropriate), binomial regression with a log link was used to calculate relative risks for binary outcomes, Poisson
regression with robust standard errors was used
to calculate rate ratios for count data, and linear
regression was used for continuous outcomes.
Effect sizes and corresponding 95% confidence
intervals are presented for all comparisons. A
Kaplan–Meier cumulative incidence curve was
used to describe the incidence of appendectomy
over time in the antibiotics group, both overall
and according to appendicolith status. Data are
current as of June 4, 2020 (the final day of the
90-day survey window for the last patient). All
analyses were performed with the use of R statistical software, version 3.5.0 (R Foundation for
Statistical Computing).

R e sult s
Population

From May 3, 2016, through February 5, 2020, a
total of 8168 patients underwent screening, of
whom 1589 (19%) were ineligible for enrollment
in the trial for clinical or appendicitis-related
reasons (Fig. 1). A total of 1552 participants
(31% of the patients who were eligible) underwent randomization; 776 were assigned to receive
antibiotics, and 776 to undergo appendectomy
(Table S2). Sociodemographic and clinical characteristics of the participants were similar in the
two groups (Table 1 and Table S3). Imaging to
confirm appendicitis was computed tomography
(CT) alone or in combination with ultrasonography or magnetic resonance imaging in 96% of
the participants. An appendicolith was found on
imaging in 27% of the participants.
n engl j med 383;20

In the antibiotics group, 51% of the participants were admitted to the hospital for the index
treatment, whereas 47% (range across sites, 0 to
81%) were discharged from the emergency department to home, of whom 79% were discharged within 24 hours after randomization;
the remaining 2% had another discharge disposition (e.g., were in the observational unit). In the
appendectomy group, 95% of the participants
were admitted to the hospital for the index treatment, and 96% of the appendectomy procedures
were performed laparoscopically. The mean time
from randomization to discharge from either
the emergency department or the hospital for
the index treatment was 1.33 days in the antibiotics group and 1.30 days in the appendectomy
group (Table 2). At least one additional course of
antibiotics was prescribed within 90 days after
the index treatment in 73 of 676 participants
(11%) in the antibiotics group with 90-day follow-up data. Adherence to the treatment, as reported by sites, was 90% among participants in
the antibiotics group and more than 99% among
those in the appendectomy group.
Primary and Secondary Clinical Outcomes

The primary outcome, the mean 30-day EQ-5D
score, was 0.92±0.13 in the antibiotics group
and 0.91±0.13 in the appendectomy group (difference, 0.01 points; 95% confidence interval
[CI], −0.001 to 0.03); these findings are consistent with noninferiority of antibiotics to appendectomy. Results were similar in the per-protocol
analysis (difference, 0.01 points; 95% CI, −0.002
to 0.03) and in an analysis performed with the
use of multiple imputation for missing primaryoutcome data (difference, 0.01 points; 95% CI,
−0.004 to 0.02).
Results in subgroups of participants with an
appendicolith and those without an appendicolith also showed noninferiority of antibiotics with
respect to the primary outcome (Table 2). In the
antibiotics group, appendectomy had been performed in 11% of the participants by 48 hours,
in 20% by 30 days, and in 29% by 90 days
(Fig. 2); the 90-day incidence of appendectomy
was 41% among those with an appendicolith
and 25% among those without an appendicolith.
Table 2 shows results for additional secondary
outcomes, both overall and according to appendicolith status. The percentage of participants
who had resolution of symptoms (i.e., the ab-
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Table 1. Sociodemographic and Clinical Characteristics of the Patients at Baseline.*
Characteristic

Antibiotics
(N = 776)

Appendectomy
(N = 776)

Age — yr

38.3±13.4

37.8±13.7

Sex — no. (%)
Female

286 (37)

290 (37)

Male

490 (63)

486 (63)

8 (1)

6 (1)

White

461 (60)

449 (59)

Black

75 (10)

63 (8)

Gender different from sex assigned at birth — no. (%)
Race or ethnic group — no. (%)†

American Indian or Alaska Native

13 (2)

9 (1)

Asian

39 (5)

53 (7)

Native Hawaiian or Pacific Islander

4 (1)

3 (<1)

Multiple or other

176 (23)

185 (24)

Hispanic ethnic group†

362 (47)

366 (47)

English

469 (60)

464 (60)

Spanish

267 (34)

267 (34)

40 (5)

45 (6)

323 (43)

317 (42)

Primary language — no. (%)

Other
Insurance — no. (%)
Commercial
Medicare or Tricare
Medicaid or other state program
Other or no coverage

89 (12)

89 (12)

134 (18)

131 (17)

213 (28)

217 (29)

Modified Charlson comorbidity index score‡

0.24±0.53

0.24±0.53

Body-mass index§

29.0±6.6

28.6±6.1

Duration of symptoms — days

1.8±3.6

1.6±1.6

Alvarado score¶

6.6±1.6

6.7±1.7

History of fever — no. (%)
Initial white-cell count — per μl

194 (25)

185 (24)

12,900±4000

13,400±4100

626 (81)

609 (78)

Imaging test — no. (%)
Computed tomography alone
Ultrasonography alone
>1 Imaging test

24 (3)

30 (4)

125 (16)

137 (18)

*	Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. Data were missing for 26 partici‑
pants in the antibiotics group and 30 participants in the appendectomy group for gender different from sex assigned
at birth; 8 and 14 participants, respectively, for race or ethnic group; 17 and 22 for insurance; 3 and 2 for modified
Charlson comorbidity index score; 209 and 104 for body-mass index; 1 and 1 for duration of symptoms; 38 and 38 for
Alvarado score; 0 and 1 for history of fever; and 3 and 1 for initial white-cell count. Additional information regarding
patient characteristics is provided in Table S3.
†	Race and ethnic group were reported by the participant. If the participant did not report the information and it was
listed in the participant’s chart, the information from the chart was used.
‡	Scores on the modified Charlson comorbidity index range from 0 to 40, with lower scores indicating fewer coexisting
conditions and a lower short-term risk of death.
§	Body-mass index is the weight in kilograms divided by the square of the height in meters.
¶	Alvarado scores range from 0 to 10, with higher scores indicating a higher likelihood of having appendicitis.
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sence of pain, tenderness, and fever) was similar
in the two groups by 7, 14, and 30 days. The
percentage with a visit to the emergency department or urgent care clinic after the index treatment was 9% in the antibiotics group and 4% in
the appendectomy group, and the percentage
with any hospitalization after the index treatment (including for eventual appendectomy) was
24% and 5%, respectively. The mean number of
missed work days for participants was 5.26 in
the antibiotics group and 8.73 in the appendectomy group, and the mean number of missed
work days for caregivers was 1.33 and 2.04, respectively. Appendiceal neoplasms were identified in nine participants (mean age, 47±17 years;
range, 21 to 74) — seven in the appendectomy
group and two in the antibiotics group who had
undergone appendectomy. Eight of the neoplasms
were carcinomas, and one was a mucocele.

Identification of an appendiceal perforation
during an operation or on pathological review
was less common in the antibiotics group than
in the appendectomy group (occurring in 9% vs.
15% of the participants), but the majority of
participants in the antibiotics group did not
have surgery and thus could not be assessed.
When the analysis was limited to participants in
either group who had undergone appendectomy,
the percentage with a perforation was higher in
the antibiotics group than in the appendectomy
group (32% vs. 16%); the higher rate in the antibiotics group overall was attributable to those
with an appendicolith (61% vs. 24%) and not to
those without an appendicolith (14% vs. 13%).
The rate of use of more extensive procedures
(small-bowel or colon resection, reoperation,
laparotomy, colostomy, or ileostomy) was low
and similar in the two groups (1.0 vs. 0.8 per
100 participants).

Adverse Events

There were no deaths (Table 3 and Table S4). The
rate of serious adverse events was 4.0 per 100
participants in the antibiotics group and 3.0 per
100 participants in the appendectomy group
(rate ratio, 1.29; 95% CI, 0.67 to 2.50). The rate
of NSQIP-defined complications was 8.1 per 100
participants in the antibiotics group and 3.5 per
100 participants in the appendectomy group
(rate ratio, 2.28; 95% CI, 1.30 to 3.98), and at
least one such event occurred in 5% and 3% of
the participants, respectively. The higher rate in
the antibiotics group overall was attributable to
those with an appendicolith (20.2 vs. 3.6 per 100
participants) and not to those without an appendicolith (3.7 vs. 3.5 per 100 participants). The
rate of site-related infectious complications (incisional or organ–space infections) was also
higher among those with an appendicolith.
Percutaneous drainage procedures were more
common in the antibiotics group than in the
appendectomy group overall (2.5 vs. 0.5 per 100
participants; rate ratio, 5.36; 95% CI, 1.55 to
18.50) and particularly among those with an appendicolith. Reactions to antibiotics that led to
a health care encounter were more common in
the antibiotics group than in the appendectomy
group (3.3 vs. 0.2 per 100 participants), with one
reaction in the antibiotics group classified as
life-threatening. The rate of C. difficile infection
was 0.6 per 100 participants in the two groups.

n engl j med 383;20

Discussion
In this large, randomized trial of antibiotics for
appendicitis, antibiotics were noninferior to appendectomy on the basis of results of a commonly used measure of health status at 30 days.
By 90 days, 29% of the participants in the antibiotics group had undergone appendectomy, including 41% of those with an appendicolith and
25% of those without an appendicolith. NSQIPdefined complications were more common in the
antibiotics group than in the appendectomy group
but were attributable to participants with an appendicolith, who additionally appeared to have a
higher risk of serious adverse events than those
without an appendicolith. By 1 week, resolution
of symptoms of appendicitis was similar in the
two groups. Nearly half the participants assigned to receive antibiotics were not hospitalized for the index treatment. Participants and
their caregivers in the antibiotics group missed
less time from work than those in the appendectomy group, but emergency department visits
and hospitalizations after the index treatment
were more common in the antibiotics group.
The EQ-5D score at 30 days was selected as
the primary outcome because it is a validated
measure of overall health status responsive to
appendicitis treatment,21 and the time period is
typical for recovery from appendectomy. Numer-
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Overall

55/618 (9)

66/615
(0.11)

2516/478
(5.26)
679/509
(1.33)

Any visit to emergency department or
urgent care clinic after index
treatment within 90 days — no./
total no. (%)‖

n engl j med 383;20

Visits to emergency department or urgent
care clinic after index treatment
within 90 days — no. of visits/
no. of participants (mean)‡

nejm.org

Days of missed work for participant
within 90 days — no. of days/
no. of participants (mean)‡

Days of missed work for caregiver within
90 days — no. of days/no. of care‑
givers (mean)‡

1009/495
(2.04)

0.66
(0.48 to 0.91)††

0.63
(0.51 to 0.77)††

2.64
(1.57 to 4.43)††

2.07
(1.32 to 3.25)**

4.38
(2.49 to 7.73)††

4.62
(3.21 to 6.65)**

1.00
(0.89 to 1.13)††

242/137
(1.77)

743/121
(6.14)

17/163
(0.10)

14/165 (8)

191/166
(1.15)

57/176 (32)

403/212
(1.90)

213/126
(1.69)

1134/125
(9.07)

2/153
(0.01)

2/153 (1)

37/156
(0.24)

8/157 (5)

330/202
(1.63)

111/163
(68)

1.04
(0.56 to 1.92)††

0.72
(0.48 to 1.09)††

8.19
(2.03 to 33.00)††

6.49
(1.50 to 28.09)**

4.55
(1.46 to 14.18)††

6.36
(3.13 to 12.90)**

1.15
(0.89 to 1.47)††

1.02
(0.88 to 1.18)**

0.98
(0.82 to 1.18)**

0.81
(0.64 to 1.03)**

−0.01
(−0.03 to 0.02)§

Effect (95% CI)
0.91±0.13

Surgery

437/372
(1.17)

1773/357
(4.97)

49/452
(0.11)

41/453 (9)

230/456
(0.50)

97/459 (21)

626/564
(1.11)

796/369
(2.16)

2997/348
(8.61)

22/446
(0.05)

24/451 (5)

56/453
(0.12)

24/456 (5)

679/574
(1.18)

337/496 (68) 355/500 (71)

343/503 (68) 333/502 (66)

0.56
(0.38 to 0.82)††

0.60
(0.48 to 0.76)††

2.15
(1.23 to 3.76)††

1.70
(1.05 to 2.77)**

4.07
(2.24 to 7.41)††

4.02
(2.62 to 6.16)**

0.92
(0.82 to 1.05)††

0.96
(0.88 to 1.04)**

1.03
(0.94 to 1.12)**

1.04
(0.92 to 1.16)**

0.02
(0.003 to 0.03)§

Effect (95% CI)

Appendicolith Absent

279/525 (53) 259/505 (51)

0.92±0.13

Antibiotics

of

4131/473
(8.73)

24/599
(0.04)

26/604 (4)

93/609
(0.15)

32/613 (5)

1010/776
(1.30)

0.97
125/180 (69)
(0.91 to 1.04)**

102/176
(58)

85/183 (46)

0.92±0.13

Surgery

Appendicolith Present

71/189 (38)

0.92±0.14

Antibiotics

1.02
103/182 (57)
(0.94 to 1.10)**

0.99
(0.89 to 1.10)**

0.01
(−0.001 to 0.03)§

Effect (95% CI)

n e w e ng l a n d j o u r na l

*	Plus–minus values are means ±SD. Confidence intervals for secondary outcomes and subgroup analyses were not adjusted for multiple comparisons; thus, they are exploratory and
should not be used to infer definitive treatment effects.
†	Scores on the European Quality of Life–5 Dimensions (EQ-5D) questionnaire range from 0 to 1, with higher scores indicating better health status; the minimal clinically important dif‑
ference is 0.05 points.
‡	The overall analysis was adjusted for recruitment site and appendicolith status, and the subgroup analyses were adjusted for recruitment site.
§	The effect is a mean difference.
¶	Resolution of symptoms was defined as the absence of pain, tenderness, and fever.
‖	The overall analysis was adjusted for appendicolith status, and the subgroup analyses were unadjusted.
**	The effect is a relative risk.
††	The effect is a rate ratio.

421/622
(0.68)

Days in hospital after index treatment
within 90 days — no. of days/
no. of participants (mean)‡

Any hospitalization after index treatment 154/635 (24)
within 90 days — no./total no. (%)‖

1030/776
(1.33)

462/676 (68) 466/663 (70)

By 30 days

Days from randomization to discharge
for index treatment — no. of days/
no. of participants (mean)‡

446/685 (65) 435/678 (64)

By 14 days

0.91±0.13

Surgery

350/714 (49) 344/688 (50)

0.92±0.13

Antibiotics

By 7 days

Resolution of symptoms — no./total no.
(%)¶‖

EQ-5D at 30 days†‡

Outcome

Table 2. Intention-to-Treat Comparison of Patient-Reported Outcomes, Clinical Outcomes, Time Spent in Health Care Settings, and Missed Work.*
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Cumulative Incidence (95% CI)
Overall
Appendicolith Absent
Appendicolith Present

48 Hr

30 Days

90 Days

0.11 (0.09–0.14)
0.08 (0.05–0.10)
0.22 (0.16–0.27)

0.20 (0.17–0.23)
0.16 (0.13–0.19)
0.31 (0.25–0.37)

0.29 (0.26–0.32)
0.25 (0.21–0.29)
0.41 (0.33–0.47)

1.00

Cumulative Incidence of Appendectomy

0.90
0.80
0.70
0.60
0.50
0.40
0.30
0.20
Overall
Appendicolith absent
Appendicolith present

0.10
0.00

0

14

28

42

56

70

84

Days since Randomization
No. at Risk
Overall
Appendicolith absent
Appendicolith present

776
564
212

616
470
146

589
448
141

542
411
131

518
394
124

499
381
118

485
371
114

0
0
0

141
79
62

151
86
65

170
102
68

184
112
72

203
125
78

212
131
81

Cumulative No. of Events
Overall
Appendicolith absent
Appendicolith present

Figure 2. Cumulative Incidence of Appendectomy in the Antibiotics Group.
Plus signs indicate censoring because the participant withdrew or was lost to follow‑up.

ous secondary outcomes — including appendectomy (if the participant was initially treated with
antibiotics), complications, time spent in health
care settings, and missed work — are also recognized as important considerations in decision
making. Another relevant outcome is the potential for missed neoplasm in patients who are not
undergoing appendectomy. Although almost all
participants underwent CT, and those with evidence suggestive of a mass were excluded, nine
neoplasms were identified in the appendectomy
specimens. Of note, fewer neoplasms were found
among participants in the antibiotics group, and
it is unknown whether earlier detection affected
patient outcomes.
The CODA trial enrolled patients who had
more severe appendicitis than patients in previous trials and included those with an appendin engl j med 383;20

colith. Although appendicoliths are commonly
identified on CT and are found in approximately
20% of pathological specimens from patients
with and without appendicitis,23 their effect on
treatment success is unclear. Appendicoliths have
been linked to a higher rate of complicated appendicitis,24-26 so patients with an appendicolith
were included in a prespecified subgroup in our
trial. The broad inclusion criteria of the CODA
trial may in part explain the differences in outcomes between our trial and the Appendicitis
Acuta (APPAC) trial, the largest previous randomized trial addressing this question (with 530
total patients).7 The APPAC trial excluded patients
with an appendicolith and approached only 30%
of all patients with appendicitis. In the APPAC
trial, the incidence of appendectomy in the antibiotics group was 16% at 90 days (Salminen P:
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1/656 (0.2)

4/656 (0.6)

Reaction to antibiotics that led to a
22/676 (3.3)
health care encounter
— no. of events/no. of
participants (events per
100 participants)
4/676 (0.6)

0/183

6/183 (3.3)

12/183 (6.6)

22/210 (10.5)

37/183 (20.2)

26/183 (14)

10/183 (5.5)

17/183 (9.3)

11/183 (6)

Antibiotics

0/169

0/169

1/169 (0.6)

7/200 (3.5)

6/169 (3.6)

5/169 (3)

6/169 (3.6)

6/169 (3.6)

6/169 (4)

Surgery

NA

NA

11.08
(1.42 to 86.55)

2.99
(1.30 to 6.92)

5.69
(2.11 to 15.38)

4.80
(1.89 to 12.22)

1.54
(0.55 to 4.30)

2.62
(0.95 to 7.24)

1.69
(0.64 to 4.48)

Effect
(95% CI)†

4/493 (0.8)

16/493 (3.2)

5/493 (1.0)

11/561 (2.0)

18/493 (3.7)

11/493 (2)

9/493 (1.8)

4/487 (0.8)

1/487 (0.2)

2/487 (0.4)

14/569 (2.5)

17/487 (3.5)

16/487 (3)

13/487 (2.7)

14/487 (2.9)

13/487 (3)

Surgery

0.99
(0.21 to 4.63)

15.81
(2.07 to 120.50)

2.47
(0.48 to 12.67)

0.80
(0.33 to 1.92)

1.05
(0.45 to 2.43)

0.68
(0.32 to 1.45)

0.68
(0.26 to 1.80)

0.71
(0.28 to 1.76)

0.61
(0.25 to 1.45)

Effect (95% CI)†

Appendicolith Absent

10/493 (2.0)

8/493 (2)

Antibiotics

*	All overall analyses were adjusted for appendicolith status, and all subgroup analyses were unadjusted. NA denotes not applicable.
†	The effect is a relative risk for participants with ≥1 event and is a rate ratio for all other outcomes.
‡	Individual frequencies for National Surgical Quality Improvement Program (NSQIP)–defined complications are provided in Table S4.
§	Site-related infectious complications were defined as incisional infections or organ–space infections (abscesses) that had occurred at 30 days.

0.99
(0.21 to 4.63)

21.36
(2.86 to 159.67)

5.36
(1.55 to 18.50)

1.54
(0.87 to 2.72)

2.28
(1.30 to 3.98)

1.72
(1.02 to 2.90)

0.96
(0.48 to 1.91)

1.29
(0.67 to 2.50)

0.97
(0.52 to 1.80)

Effect
(95% CI)†

Appendicolith Present

of

Clostridioides difficile colitis — no. of
events/no. of partici‑
pants (events per 100
participants)

3/656 (0.5)

21/769 (2.7)

23/656 (3.5)

21/656 (3)

17/676 (2.5)

33/771 (4.3)

55/676 (8.1)

37/676 (5)

19/656 (2.9)

20/656 (3.0)

19/656 (3)

Surgery

Overall
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Drainage procedure

Site-related infectious
complication§

Total events — no. of events/no.
of participants (events
per 100 participants)

Participants with ≥1 event — no./
total no. (%)

NSQIP-defined complications‡

19/676 (2.8)

27/676 (4.0)

Total events — no. of events/no.
of participants (events
per 100 participants)

Unplanned hospitalization not
for appendectomy

19/676 (3)

Antibiotics

Participants with ≥1 event — no./
total no. (%)

Serious adverse events

Event

Table 3. Adverse Events and Complications at 90 Days.*
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personal communication), 27% at 1 year, and
39% at 5 years.27 The percentage of patients who
were found to have a perforation during the index appendectomy procedure was less than 2% in
the APPAC trial,7 as compared with 16% in the
appendectomy group in the CODA trial (13%
among those without an appendicolith), a finding consistent with the greater severity of appendicitis in our trial population. The rate of
perforation identified in the CODA trial is consistent with rates reported in population studies
of appendicitis.28 Disease severity, particularly
related to the presence of an appendicolith, may
have also contributed to our finding of a higher
risk of abscess formation and drainage procedures in the antibiotics group, although these
were uncommon events. In our trial, most appendectomy procedures were laparoscopic and
nearly half the participants in the antibiotics
group received the antibiotics in the emergency
department (avoiding hospitalization for the index treatment), whereas in the APPAC trial, surgeons used only open surgical techniques and
hospital stays were required in both treatment
groups. These differences probably explain the
higher observed rate of site-related infectious
complications in the appendectomy group and
the longer hospitalizations in both treatment
groups in the APPAC trial than in the CODA
trial.7 Of note, both trials showed that missed
work was less frequent in the antibiotics group.
A recent meta-analysis of five randomized trials
showed lower complication rates and shorter
disability with antibiotic treatment than with
appendectomy.29
This report has the following limitations. It
includes only 90-day follow-up data and thus
underrepresents recurrence and long-term complications; ongoing follow-up will inform longerterm outcomes. Although almost all patients with
appendicitis were approached for participation
in the trial, only approximately 30% of eligible
patients agreed to undergo randomization, with
variation in this percentage across sites, and this
factor may have introduced selection bias; a parallel observational cohort study that includes
approximately 500 patients who selected their
treatment is currently ongoing. Because this was
a pragmatic trial, the protocol did not specify
requirements for hospitalization or for a given
antibiotic regimen. The trial was not blinded,
and this factor may have influenced several outn engl j med 383;20

comes, including the primary outcome. In addition, some patients in the appendectomy group
declined surgery, and some patients in the antibiotics group underwent appendectomy without
meeting protocol-specified criteria for surgery.
In a small previous study, Talan et al.30 found
that outpatient management was feasible. In the
CODA trial, patients were selected to receive
antibiotics on an outpatient basis according to
protocol-specified discharge criteria, and rates
of use varied greatly across sites. Because of expected confounding related to site and patient
characteristics, we did not assess outcomes according to outpatient or inpatient treatment.
Although we prespecified a plan to assess outcomes according to the presence or absence of
an appendicolith, our observations in these subgroups must be considered in the context of the
small numbers of several individual complications. Furthermore, there was no adjustment for
multiple testing of secondary outcomes.
This comparative effectiveness trial showed
that, for the treatment of appendicitis, antibiotics
were noninferior to appendectomy on the basis
of results of a standardized measure of general
health status, at least in the short term. In the
antibiotics group, nearly 3 in 10 participants had
undergone appendectomy by 90 days, and there
were more emergency department visits and hospitalizations after the index treatment than in
the appendectomy group. An alternative perspective is that, in the antibiotics group, more than
7 in 10 participants avoided surgery, many were
treated on an outpatient basis, and participants
and caregivers missed less time at work than
with appendectomy. In the antibiotics group,
participants with an appendicolith were at a
higher risk for both appendectomy and complications than participants without an appendicolith. These data may be particularly relevant
during the Covid-19 pandemic, as patients and
clinicians weigh the benefits and risks of each
approach, considering individual characteristics,
preferences, and circumstances.
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